Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Trading Down 41.2 %

NASDAQ TRVN opened at $1.47 on Monday. The stock has a fifty day simple moving average of $4.41 and a 200-day simple moving average of $7.19. The stock has a market cap of $1.25 million, a PE ratio of -0.55 and a beta of 1.02. Trevena has a twelve month low of $1.13 and a twelve month high of $19.23.

Trevena (NASDAQ:TRVN) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($9.25) by $9.02. The company had revenue of $0.33 million during the quarter. Research analysts predict that Trevena will post -32.25 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.